Low vaccination rates threaten children
Only 68 per cent of children in Khyber-Pakhtunkhwa have been immunized against various diseases, leaving 32 per cent without full vaccination coverage.
Approximately 19,000 parents in the province are reportedly reluctant to vaccinate their children.
The rising number of measles and diphtheria cases presents a serious challenge for the health department.
These views were expressed by health experts at a seminar organized by Expanded Program on Immunization (EPI) in Peshawar.
The event marked the launch of World Immunization Week, which will be observed from April 24 to April 30.
During this week, various activities will be held at the community level to promote vaccination and awareness.
The ceremony was attended by Health Secretary Shahidullah, DG Health Dr Salim, EPI Director Dr Asghar, UNICEF head Dr Inamullah, WHO Head Dr Babar Alam, and Pakistan Pediatric Association Khyber-Pakhtunkhwa President Dr Bawar Shah, among others.
Dr Asghar said that the trend of not vaccinating children against diseases in K-P poses a significant threat to public health.
Unfortunately, the COVID-19 pandemic affected vaccination rates, and now the province has devised an immunization strategy involving all partners, district coordinators, and polio officers.
The health department is working to increase human resource capacity, train medical officers, and integrate the polio program with EPI program.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
20 hours ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
Express Tribune
4 days ago
- Express Tribune
US CDC COVID vaccine advisor Dr. Lakshmi Panagiotakopoulos resigns: Reuters
Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed U.S. flag in this illustration taken December 11, 2021. Photo:REUTER Listen to article Pediatric infectious disease expert Dr Lakshmi Panagiotakopoulos of the US CDC resigned on Tuesday as co-leader of a working group that advises outside experts on COVID-19 vaccines and is leaving the agency, said two sources familiar with the move. Panagiotakopoulos said in an email to work group colleagues that her decision to step down was based on the belief she is "no longer able to help the most vulnerable members" of the US population. In her role at the Centers for Disease Control and Prevention's working group of the Advisory Committee on Immunization Practices, she co-led the gathering of information on topics for presentation. Her resignation comes one week after Health Secretary Robert F Kennedy Jr, a long-time vaccine skeptic who oversees the CDC, the Food and Drug Administration and the National Institutes of Health, said the COVID vaccine for healthy children and healthy pregnant women had been removed from the CDC's recommended immunization schedule. The move was a departure from the process in which ACIP experts meet and vote on changes to the immunization schedule or recommendations on who should get vaccines before the agency's director made a final call. The committee had not voted on the changes announced by Kennedy and the CDC does not yet have a permanent director. Two days after Kennedy's announcement, the CDC published a vaccine schedule online saying that COVID-19 vaccines remain an option for healthy children aged 6 months to 17 years when parents and doctors agree that it is needed. It had previously recommended updated COVID vaccines for everyone aged six months and older, following the guidance of the panel of outside experts. Two sources said Panagiotakopoulos did not include a specific reason for her departure. Panagiotakopoulos did not return requests for comment. "Unfortunately for me, this is a personal decision," Panagiotakopoulos wrote in an email to members of the working group that was read to Reuters by a source who received it. "My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role." The committee is scheduled to meet on June 25-27 and is expected to deliberate and vote on recommendations for use of COVID-19 vaccines, according to one of the sources who was not authorized to speak publicly.
Business Recorder
4 days ago
- Business Recorder
Communicable diseases: Need for collaboration to create awareness stressed
ISLAMABAD: The Director General (DG) Health of Federal Directorate of Immunization (FDI) has stressed the need for close collaboration between the government agencies and the civil society organisations (CSOs) to create awareness on various communicable viral diseases including poliovirus. Speaking at an event, Dr Shabana Saleem, DG Health FDI here on Tuesday said that SCOs engagement will help bridge remaining gaps in routine immunisation coverage, especially in remote and underserved areas through advocacy, demand generation, and service delivery. The meeting marked the beginning of a transformative phase in Pakistan's Expanded Programme on Immunisation (EPI), highlighting the significant role CSOs can play in reaching underserved populations. Dr Saleem welcomed representatives from CSOs, partner organisations, and the EPI community, expressing gratitude to Gavi, Mannion Daniels (MD), Oxford Policy Management (OPM), and the 17 selected CSOs from all the four provinces for their commitment and participation. 'CSOs bring community trust, local knowledge, and grassroots presence, making them essential partners in strengthening our immunisation programme,' said Dr Saleem. These CSOs will play a pivotal role in identifying 'zero-dose' children, mobilising communities, and extending EPI services where they are needed most. The CSOs will operate as a vital extension of national and provincial EPI systems. Federal and provincial governments' leadership in CSO engagement exemplifies how strategic collaboration can drive higher immunisation coverage. Through the government's strong commitment to work closely with CSOs at the provincial level, the immunisation programme will be further strengthened to reach more children, especially those that have proven hardest to reach, stated Carrie Madison Gheen, Senior Country Manager, Gavi, the Vaccine Alliance. Karen Stephenson, Team Lead for the CSO Fund Manager Mechanism at Mannion Daniels stated: 'We are delighted that thanks to the collaboration with the FDI and Provincial partners, a diverse range of civil society organizations are now able to support Pakistan's efforts to increase immunization coverage. Civil society organizations will be able to deliver meaningful results together with the communities they work in.' Under Gavi's CSO Fund Manager Mechanism, Mannion Daniels and Oxford Policy Management are responsible for delivering fund management services. To date, this has involved a rigorous independent shortlisting and due diligence process including consultation with federal and provincial EPI leadership. This resulted in the selection of 17 CSOs to support immunisation efforts across Pakistan. Following this shortlisting and selection process, the CSO Fund Manager Mechanism in Pakistan now enters the grant implementation phase. At this point, Dr Saleem emphasised the importance of coordination between CSOs, the FDI, Provincial EPIs, and development partners. 'Clear KPIs and robust monitoring frameworks will guide this initiative to ensure transparency, accountability, and measurable results,' she stated. 'I urge all CSO partners to embrace this responsibility with integrity and commitment.' Dr Saleem thanked all participants for their dedication. 'Together, let's make this partnership a model of how governments and civil society can work hand in hand to ensure every child in Pakistan receives life-saving vaccines, regardless of geography or background.' Copyright Business Recorder, 2025
